KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Profit After Tax: 2011-2024

Historic Profit After Tax for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to -$51.7 million.

  • Esperion Therapeutics' Profit After Tax fell 6.13% to -$31.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$105.8 million, marking a year-over-year decrease of 21.97%. This contributed to the annual value of -$51.7 million for FY2024, which is 75.27% up from last year.
  • Per Esperion Therapeutics' latest filing, its Profit After Tax stood at -$51.7 million for FY2024, which was up 75.27% from -$209.2 million recorded in FY2023.
  • Over the past 5 years, Esperion Therapeutics' Profit After Tax peaked at -$51.7 million during FY2024, and registered a low of -$269.1 million during FY2021.
  • Moreover, its 3-year median value for Profit After Tax was -$209.2 million (2023), whereas its average is -$164.9 million.
  • In the last 5 years, Esperion Therapeutics' Profit After Tax plummeted by 87.47% in 2021 and then surged by 75.27% in 2024.
  • Yearly analysis of 5 years shows Esperion Therapeutics' Profit After Tax stood at -$143.6 million in 2020, then tumbled by 87.47% to -$269.1 million in 2021, then grew by 13.17% to -$233.7 million in 2022, then climbed by 10.45% to -$209.2 million in 2023, then surged by 75.27% to -$51.7 million in 2024.